文献速递消化系统肿瘤

原发肿瘤部位与RAS/BRAF突变状态对奥沙利铂联合贝伐珠单抗一线治疗转移性结直肠癌的预后影响:AIO KRK0207试验分析

Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
PubMed 文献 · Eur J Cancer · 2018-07-20

基于AIO KRK0207随机试验的成熟生存数据,754例接受贝伐珠单抗+奥沙利铂+氟尿嘧啶一线诱导治疗的转移性结直肠癌患者中,左半肿瘤中位总生存24.8个月,右半为18.4个月(HR 1.54, 95%CI 1.30-1.81, P<0.0001);原发部位是多变量模型中最强预后因素(HR 1.60)。在已知RAS/BRAF状态的567例中,BRAF突变预后最差(HR 3.16),但原发部位在BRAF野生型亚组中仍具预后意义,而在RAS突变肿瘤中影响不大。

要点

  • 右半转移性结直肠癌一线贝伐珠单抗联合奥沙利铂方案预后显著差于左半(中位OS 18.4 vs 24.8个月)。
  • 原发部位是多变量分析中最强预后因素,独立于体力状态、转移部位数、CEA和血小板。
  • BRAF突变预后最差(HR 3.16),但原发部位在BRAF野生型中仍有预后价值,RAS突变中影响小。

核心结论

  • 在统一的一线贝伐珠单抗联合奥沙利铂化疗框架下,原发肿瘤部位对生存预后有重要但非唯一决定性的影响。
  • 原发部位在RAS突变肿瘤中预后影响似乎较低。

研究设计与样本

  • 基于随机对照AIO KRK0207试验的成熟生存数据进行的回顾性预后分析。
  • 754例患者均接受贝伐珠单抗+奥沙利铂+氟尿嘧啶一线诱导治疗,原发部位通过手术、病理和内镜报告回顾性确定。
  • 预后分析采用Kaplan-Meier法和log-rank检验,风险比(HR)及多变量结果来自Cox模型。

主要发现

  • 左半肿瘤患者中位总生存24.8个月,右半为18.4个月(HR 1.54, 95%CI 1.30-1.81, P<0.0001)。
  • 多变量模型中原发部位是最强预后因素(HR 1.60),体力状态、转移部位数、基线CEA和血小板也独立保留预后意义。
  • 已知RAS/BRAF状态的567例(75%)中,BRAF突变预后最差(HR 3.16)。
  • 原发部位在BRAF野生型亚组中仍是显著预后因素,但在RAS突变肿瘤中未见主要影响。

临床怎么用

  • 一线治疗决策时可结合原发肿瘤部位评估转移性结直肠癌预后,右半肿瘤预后较差。
  • 在RAS突变肿瘤中,原发部位的预后权重可能较低,需结合分子分型综合判断。
  • BRAF突变患者预后极差,应作为独立的不良预后因素纳入临床评估。

局限性

  • 原发部位为回顾性确定,非预设分析。
  • RAS/BRAF状态仅在75%患者中已知,存在缺失数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The major prognostic relevance of primary tumour location (LPT) in advanced colorectal cancer was shown in large retrospective studies, but quantitative estimates are highly heterogeneous, and there is still limited information about its impact within the framework of biomarker-guided treatment strategies. Therefore, we analysed LPT in relation to other clinical and molecular parameters, based on mature survival data from the recent randomised AIO KRK0207 trial. METHODS: Patients uniformly received first-line induction treatment with a combination of bevacizumab, oxaliplatin and fluoropyrimidine. LPT was retrospectively determined using surgical reports, pathology reports and endoscopy reports. The prognostic analyses were performed using Kaplan-Meier estimations and log-rank tests, while hazard ratios (HRs) and multivariable results were derived from Cox models. RESULTS: Among 754 patients with unequivocal information on LPT, patients with left-sided tumours showed a median overall survival of 24.8 months compared with the right-sided cohort with 18.4 months (HR: 1.54, 95% confidence interval: 1.30-1.81, P < 0.0001). In a multivariable model, LPT proved to be the strongest prognosticator (HR 1.60), with performance status, number of metastatic sites, baseline carcinoembryonic antigen (CEA) and platelets independently retaining prognostic significance. In the subgroup of patients with known RAS/BRAF status (n = 567, 75%), a BRAF mutation showed the greatest unfavourable impact (HR 3.16). Although BRAF is strongly correlated to LPT, the latter remained a significant prognosticator in the BRAF wild-type subgroup. In contrast, no major impact of LPT was seen on tumours carrying RAS mutations. CONCLUSIONS: Within the framework of a uniform treatment strategy according to the current standards, LPT proved to have an important, although not solely dominating, relevance for survival prognosis. Its impact seems to be low in tumours with a RAS mutation. REGISTRATION: ClinicalTrials.govNCT00973609.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, et al. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. Eur J Cancer. 2018. PMID: 30036739. doi:10.1016/j.ejca.2018.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。